target-selector-mutation-test-kit Videos
1 videos found
Biocept, Inc. (NASDAQ:BIOC) CEO Mike Nall tells Proactive it has received more than 250,000 samples received to date for coronavirus processing through its RT-PCR technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory. Nall says he expects COVID-19 RT-PCR testing will be a significant component of the business until the pandemic subsides, however, he says the group ...
Apr. 8, 2021
ByBiocept